CHARLES RIVER DISCOVERY RESEARCH SERVICES GERMANY ANTML:GmbH

Their core work

Charles River Discovery Research Services Germany is the Freiburg-based preclinical oncology arm of Charles River Laboratories, one of the world's largest contract research organizations. They provide specialized preclinical cancer models — including patient-derived xenografts (PDX), organoids, and genetically engineered mouse models (GEMM) — to support drug discovery and biomarker development. In H2020 consortia, they contribute preclinical validation platforms for pediatric and solid tumor research, bridging the gap between laboratory discovery and clinical cancer therapy.

What they specialise in

How they've shifted over time

Their early H2020 work (2017-2019) centered on established preclinical platforms — building POC infrastructure with PDX models, organoids, and GEMMs for pediatric cancer. From 2019 onward, they shifted toward molecular-level understanding: membrane trafficking, secretome biology, and tumor microenvironment analysis. Their most recent project (PERSIST-SEQ, 2021) marks a decisive move into single-cell multi-omics and spatial transcriptomics, signaling a transition from model providers to data-intensive cancer biology partners.

They are evolving from a traditional preclinical model provider into a partner capable of integrating advanced single-cell and spatial omics with in vivo cancer models — increasingly valuable for precision oncology consortia.

How they like to work

Exclusively a participant — they have never coordinated an H2020 project, which is consistent with their role as a specialized service provider embedded in larger research consortia. With 56 unique partners across 13 countries from just 3 projects, they operate in large, multi-national consortia (averaging ~19 partners per project). This profile suggests a reliable specialist that teams recruit for specific preclinical capabilities rather than a consortium organizer.

Despite only 3 projects, they have built a broad network of 56 consortium partners across 13 countries, reflecting participation in large-scale European cancer research initiatives. Their reach spans most of Western and Central Europe.

What sets them apart

As part of the Charles River Laboratories group, they bring industrial-grade preclinical infrastructure — PDX libraries, GEMM colonies, organoid platforms — that most academic partners simply cannot replicate at scale. Their SME classification within H2020 combined with a global parent company gives them an unusual blend: the agility and eligibility advantages of an SME with the resources and quality systems of a multinational CRO. For consortium builders, they offer validated, reproducible preclinical cancer models under GLP-adjacent standards — a critical asset for translational oncology projects aiming at clinical impact.

Highlights from their portfolio

• ITCC-P4
  Large-scale pediatric cancer preclinical platform (2017-2023) — one of the flagship efforts to systematically build POC infrastructure for childhood solid tumors across Europe.
• PERSIST-SEQ
  Their most recent and forward-looking project (2021-2026), combining single-cell multi-omics with preclinical models to understand why tumors resist therapy — positions them at the frontier of precision oncology.